Prime Nordic has invested into Diamyd Medical, a clinical-stage diabetes company active in the field of pharmaceutical development finding a cure for autoimmune (type 1) diabetes, through development and investments in medical and stem cell technologies.
The company considers this a field that has a huge importance and potential as it is estimated that about 80,000 children develop the disease each year.
With a very experienced and strong Board & Management team headed up by Mr Ulf Hannelius, PhD, MBA coupled with an impressive International Scientific Advisory Board, Diamyd Medical can be considered a suitable candidate for a Prime Nordic investment.
A solid shareholder structure, with Avanza, Nordnet and Swedbank among the shareholders, Diamyd Medical presents a flawless balance sheet with high growth potential.
Diamyd Medical’s shares are traded on Nasdaq First North, ticker DMYD B
For more information, press only:
Kevin Shinduke Kevin.Shinduke@primenordic.com